Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

APTO

Aptose Biosciences (APTO)

Aptose Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:APTO
DateTimeSourceHeadlineSymbolCompany
24/04/202507:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
24/04/202507:00GlobeNewswire Inc.Aptose Announces Auditor Not Standing for Re-AppointmentNASDAQ:APTOAptose Biosciences Inc
23/04/202521:30GlobeNewswire Inc.Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceNASDAQ:APTOAptose Biosciences Inc
23/04/202520:04Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:APTOAptose Biosciences Inc
22/04/202507:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
04/04/202507:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
01/04/202523:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
01/04/202523:30GlobeNewswire Inc.Aptose Common Shares to Delist from Nasdaq as of April 2, 2025NASDAQ:APTOAptose Biosciences Inc
29/03/202501:46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APTOAptose Biosciences Inc
28/03/202523:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
28/03/202523:01GlobeNewswire Inc.Aptose Reports Year End 2024 Results and Corporate HighlightsNASDAQ:APTOAptose Biosciences Inc
25/03/202509:48Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:APTOAptose Biosciences Inc
25/03/202508:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
22/03/202510:14Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:APTOAptose Biosciences Inc
21/03/202511:54Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:APTOAptose Biosciences Inc
17/03/202522:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
17/03/202522:30GlobeNewswire Inc.Aptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceNASDAQ:APTOAptose Biosciences Inc
22/02/202509:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
20/02/202523:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
20/02/202523:32GlobeNewswire Inc.Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First CohortNASDAQ:APTOAptose Biosciences Inc
19/02/202508:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
19/02/202508:30GlobeNewswire Inc.Aptose Announces Reverse Share SplitNASDAQ:APTOAptose Biosciences Inc
15/02/202508:57Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:APTOAptose Biosciences Inc
14/02/202512:26Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:APTOAptose Biosciences Inc
14/02/202509:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APTOAptose Biosciences Inc
14/02/202509:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
14/02/202508:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
14/02/202508:30GlobeNewswire Inc.Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market FacilityNASDAQ:APTOAptose Biosciences Inc
12/02/202523:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APTOAptose Biosciences Inc
12/02/202523:00GlobeNewswire Inc.Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialNASDAQ:APTOAptose Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:APTO